UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Vasoactive intestinal polypeptide

Author
Rodger A Liddle, MD
Section Editor
J Thomas Lamont, MD
Deputy Editor
Shilpa Grover, MD, MPH

INTRODUCTION

Vasoactive intestinal polypeptide (VIP) is a neuropeptide that functions as a neuromodulator and neurotransmitter. It is a potent vasodilator, regulates smooth muscle activity, epithelial cell secretion, and blood flow in the gastrointestinal tract [1-3]. As a chemical messenger, it functions as a neurohormone and paracrine mediator, being released from nerve terminals and acting locally on receptor-bearing cells.

The VIP receptor is a member of a unique class of G protein-coupled receptors. These receptors share a significant degree of sequence homology (>50 percent), which distinguishes them from members of the rhodopsin/beta-adrenergic family (class I) [4]. (See "Peptide hormone signal transduction and regulation".)

MOLECULAR FORMS

Like other gastrointestinal peptides, vasoactive intestinal polypeptide (VIP) is synthesized as a precursor molecule with a signal peptide containing 22 amino acids, which is then cleaved to the active peptide of 28 amino acids [5,6]. The gene encoding this peptide resides on chromosome 6 [7]. Some studies have demonstrated local control of VIP gene expression as VIP mRNA does not always parallel the peptide product [8]. These data suggest regulation at the post-transcriptional stage may be essential for normal VIP secretion [8].

The VIP peptide is remarkably well conserved across species and is identical in human, cow, pig, rat, dog, and goat species [3]. Even across species, amino acid substitutions are conservative and usually do not result in changes in bioactivity.

Alternative peptides derived from the VIP gene include peptide histidine isoleucine (PHI) [9], peptide histidine methionine [10,11], and peptide histidine valine [6]. Although the functional significance of these peptides is unclear, PHI is known to stimulate intestinal fluid secretion [12].

      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Oct 08 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970; 169:1217.
  2. Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 1970; 225:863.
  3. Dockray GJ. Vasoactive intestinal polypeptide and related peptides. In: Gut Hormones: Biochemistry and Physiology, 1st ed, Walsh JH, Dockray GJ (Eds), Raven Press, New York 1994. p.447.
  4. Birnbaumer M. Mutations and diseases of G protein coupled receptors. J Recept Signal Transduct Res 1995; 15:131.
  5. Linder S, Barkhem T, Norberg A, et al. Structure and expression of the gene encoding the vasoactive intestinal peptide precursor. Proc Natl Acad Sci U S A 1987; 84:605.
  6. Maggi CA, Giachetti A, Dey RD, Said SI. Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins. Physiol Rev 1995; 75:277.
  7. Gozes I, Nakai H, Byers M, et al. Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24. Somat Cell Mol Genet 1987; 13:305.
  8. Gozes I, Shani Y, Rostène WH. Developmental expression of the VIP-gene in brain and intestine. Brain Res 1987; 388:137.
  9. Christofides ND, Yiangou Y, Blank MA, et al. Are peptide histidine isoleucine and vasoactive intestinal peptide co-synthesised in the same pro-hormone? Lancet 1982; 2:1398.
  10. Bodner M, Fridkin M, Gozes I. Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. Proc Natl Acad Sci U S A 1985; 82:3548.
  11. Yiangou Y, Williams SJ, Bishop AE, et al. Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome. J Clin Endocrinol Metab 1987; 64:131.
  12. Ghiglione M, Christofides ND, Yiangou Y, et al. PHI stimulates intestinal fluid secretion. Neuropeptides 1982; 3:79.
  13. Ekblad E, Winther C, Ekman R, et al. Projections of peptide-containing neurons in rat small intestine. Neuroscience 1987; 20:169.
  14. Porter AJ, Wattchow DA, Brookes SJ, Costa M. Projections of nitric oxide synthase and vasoactive intestinal polypeptide-reactive submucosal neurons in the human colon. J Gastroenterol Hepatol 1999; 14:1180.
  15. Adeghate E. Distribution of calcitonin-gene-related peptide, neuropeptide-Y, vasoactive intestinal polypeptide, cholecystokinin-8, substance P and islet peptides in the pancreas of normal and diabetic rats. Neuropeptides 1999; 33:227.
  16. Kitanishi T, Suzuki M, Kitano H, et al. Immunohistochemical detection of vasoactive intestinal polypeptide (VIP) and the VIP receptor in the rat inner ear. Acta Otolaryngol Suppl 1998; 539:52.
  17. Houdeau E, Prudhomme MJ, Rousseau JP. Regional difference in the distribution of vasoactive intestinal polypeptide-immunoreactive nerve fibres along the uterus and between myometrial muscle layers in the rat. Histochem J 1998; 30:525.
  18. Alexandre D, Anouar Y, Jegou S, et al. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals. Endocrinology 1999; 140:1285.
  19. Vertongen P, Schiffmann SN, Gourlet P, Robberecht P. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Ann N Y Acad Sci 1998; 865:412.
  20. Harmar AJ, Arimura A, Gozes I, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50:265.
  21. Fahrenkrug J. Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol 1993; 72:354.
  22. Bitar KN, Said SI, Weir GC, et al. Neural release of vasoactive intestinal peptide from the gut. Gastroenterology 1980; 79:1288.
  23. Verner JV, Morrison AB. Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med 1974; 133:492.
  24. Bloom SR. Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: value of measurement in diagnosis and treatment. Am J Dig Dis 1978; 23:373.
  25. Masel SL, Brennan BA, Turner JH, et al. Pancreatic vasoactive intestinal polypeptide-oma as a cause of secretory diarrhoea. J Gastroenterol Hepatol 2000; 15:457.
  26. Lundberg JM, Fahrenkrug J, Larsson O, Anggård A. Corelease of vasoactive intestinal polypeptide and peptide histidine isoleucine in relation to atropine-resistant vasodilation in cat submandibular salivary gland. Neurosci Lett 1984; 52:37.
  27. Holst JJ, Fahrenkrug J, Knuhtsen S, et al. VIP and PHI in the pig pancreas: coexistence, corelease, and cooperative effects. Am J Physiol 1987; 252:G182.
  28. Yasui A, Naruse S, Yanaihara C, et al. Corelease of PHI and VIP by vagal stimulation in the dog. Am J Physiol 1987; 253:G13.
  29. Li CG, Rand MJ. Nitric oxide and vasoactive intestinal polypeptide mediate non-adrenergic, non-cholinergic inhibitory transmission to smooth muscle of the rat gastric fundus. Eur J Pharmacol 1990; 191:303.
  30. Van Geldre LA, Lefebvre RA. Interaction of NO and VIP in gastrointestinal smooth muscle relaxation. Curr Pharm Des 2004; 10:2483.
  31. Fahrenkrug J, Hannibal J. Neurotransmitters co-existing with VIP or PACAP. Peptides 2004; 25:393.
  32. Barada KA, Saadé NE, Atweh SF, Nassar CF. Neural mediation of vasoactive intestinal polypeptide inhibitory effect on jejunal alanine absorption. Am J Physiol 1998; 275:G822.
  33. Cho WK, Boyer JL. Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes. Gastroenterology 1999; 117:420.
  34. Rattan S, Fan YP, Chakder S. Mechanism of inhibition of VIP-induced LES relaxation by heme oxygenase inhibitor zinc protoporphyrin IX. Am J Physiol 1999; 276:G138.
  35. Motomura Y, Chijiiwa Y, Yasuda O, et al. Thyrotropin-releasing hormone interacts with vasoactive intestinal peptide-specific receptor in guinea pig cecal circular smooth muscle cells. Regul Pept 2000; 87:41.
  36. Jiang S, Kopras E, McMichael M, et al. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res 1997; 57:1475.
  37. Goyal RK, Rattan S, Said SI. VIP as a possible neurotransmitter of non-cholinergic non-adrenergic inhibitory neurones. Nature 1980; 288:378.
  38. Grider JR. Interplay of VIP and nitric oxide in regulation of the descending relaxation phase of peristalsis. Am J Physiol 1993; 264:G334.
  39. Sababi M, Hällgren A, Nylander O. Interaction between prostanoids, NO, and VIP in modulation of duodenal alkaline secretion and motility. Am J Physiol 1996; 271:G582.
  40. Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J 2004; 18:1325.
  41. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56:249.
  42. Ganea D, Hooper KM, Kong W. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol (Oxf) 2015; 213:442.
  43. Pozo D, Gonzalez-Rey E, Chorny A, et al. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides 2007; 28:1833.
  44. Deng S, Xi Y, Wang H, et al. Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis. Cell Immunol 2010; 265:105.
  45. Arranz A, Abad C, Juarranz Y, et al. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 2008; 15:46.
  46. Jönsson M, Norrgård O, Hansson M, Forsgren S. Decrease in binding for the neuropeptide VIP in response to marked inflammation of the mucosa in ulcerative colitis. Ann N Y Acad Sci 2007; 1107:280.
  47. Neunlist M, Toumi F, Oreschkova T, et al. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am J Physiol Gastrointest Liver Physiol 2003; 285:G1028.
  48. Margolis KG, Gershon MD. Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol 2009; 25:503.
  49. Hamasaki Y, Mojarad M, Said SI. Relaxant action of VIP on cat pulmonary artery: comparison with acetylcholine, isoproterenol, and PGE1. J Appl Physiol Respir Environ Exerc Physiol 1983; 54:1607.
  50. Hamidi SA, Prabhakar S, Said SI. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J 2008; 31:135.
  51. Dewachter L, Dewachter C, Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs 2010; 19:469.
  52. Cernuda-Morollón E, Martínez-Camblor P, Ramón C, et al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache 2014; 54:987.
  53. Tajti J, Szok D, Majláth Z, et al. Migraine and neuropeptides. Neuropeptides 2015; 52:19.
  54. Moody TW, Moreno P, Jensen RT. Neuropeptides as lung cancer growth factors. Peptides 2015; 72:106.
  55. Said SI, Faloona GR. Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors. N Engl J Med 1975; 293:155.
  56. Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124:1050.
  57. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331:1116.
  58. Pallela VR, Thakur ML, Chakder S, Rattan S. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med 1999; 40:352.
  59. Palsson OS, Morteau O, Bozymski EM, et al. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004; 49:1236.
  60. Larsson LT, Sundler F. Is the reduction of VIP the clue to the pathophysiology of Hirschsprung's disease? Z Kinderchir 1990; 45:164.
  61. Aggestrup S, Uddman R, Sundler F, et al. Lack of vasoactive intestinal polypeptide nerves in esophageal achalasia. Gastroenterology 1983; 84:924.
  62. Heinz-Erian P, Dey RD, Flux M, Said SI. Deficient vasoactive intestinal peptide innervation in the sweat glands of cystic fibrosis patients. Science 1985; 229:1407.
  63. Vaidya B, Gupta V. Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery. J Control Release 2015; 211:118.
  64. Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 2007; 13:1113.